Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong
· Delayed Price · Currency is HKD
64.95
+4.00 (6.56%)
Mar 10, 2026, 2:35 PM HKT
Nanjing Leads Biolabs Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | - | - | 8.87 |
| Cost of Revenue | - | - | 3.19 |
| Gross Profit | - | - | 5.68 |
| Selling, General & Admin | 64.76 | 87.69 | 38.05 |
| Research & Development | 233.5 | 185.68 | 230.86 |
| Operating Expenses | 298.25 | 273.38 | 268.91 |
| Operating Income | -298.25 | -273.38 | -263.23 |
| Interest Expense | -7 | -5.76 | -1.4 |
| Interest & Investment Income | 9.31 | 8.29 | 6.55 |
| Currency Exchange Gain (Loss) | 1.13 | 2.04 | 2.77 |
| Other Non Operating Income (Expenses) | 6.42 | 7.96 | 3.96 |
| EBT Excluding Unusual Items | -288.39 | -260.85 | -251.35 |
| Gain (Loss) on Sale of Investments | 1.18 | 1.72 | 6.44 |
| Other Unusual Items | - | -42.08 | -117.33 |
| Pretax Income | -287.21 | -301.22 | -362.25 |
| Net Income | -287.21 | -301.22 | -362.25 |
| Net Income to Common | -287.21 | -301.22 | -362.25 |
| Shares Outstanding (Basic) | 155 | 150 | 145 |
| Shares Outstanding (Diluted) | 155 | 150 | 145 |
| Shares Change (YoY) | - | 3.56% | - |
| EPS (Basic) | -1.86 | -2.01 | -2.50 |
| EPS (Diluted) | -1.86 | -2.01 | -2.50 |
| Free Cash Flow | - | -121.79 | -204.41 |
| Free Cash Flow Per Share | - | -0.81 | -1.41 |
| Gross Margin | - | - | 64.07% |
| Operating Margin | - | - | -2969.26% |
| Profit Margin | - | - | -4086.28% |
| Free Cash Flow Margin | - | - | -2305.84% |
| EBITDA | -280.19 | -253.13 | -243.49 |
| D&A For EBITDA | 18.07 | 20.24 | 19.74 |
| EBIT | -298.25 | -273.38 | -263.23 |
Source: S&P Capital IQ. Standard template.
Financial Sources.